Prosecution Insights
Last updated: April 19, 2026
Application No. 18/462,457

DRUG DELIVERY DEVICE

Non-Final OA §102§103§112
Filed
Sep 07, 2023
Examiner
BOUCHELLE, LAURA A
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sensile Medical AG
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
90%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
952 granted / 1188 resolved
+10.1% vs TC avg
Moderate +10% lift
Without
With
+10.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
47 currently pending
Career history
1235
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
28.3%
-11.7% vs TC avg
§112
15.6%
-24.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1188 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 10, 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 10 recites the limitation "the pump engine" in line 3. There is insufficient antecedent basis for this limitation in the claim. Claim 11 inherits the deficiencies of claim 10. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-7, 10, 11, 13 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mojarrad et al (US 2020/0164155). Regarding claim 1, Mojarrad discloses a drug delivery device, comprising a delivery unit including a drug container 200 comprising a barrel portion 270 and a plunger 244 slidably mounted within the barrel portion and sealing the drug within the container at one end of the barrel portion (fig. 5B; page 4, para. 0053), and a drive unit 250 comprising a pneumatic flow system 240 and a pneumatic pumping system 250 configured to pump air via the pneumatic flow system to a space behind the plunger to generate a gas pressure to advance the plunger in the container during drug delivery (fig. 5B; page 4, para. 0053), wherein the drug delivery device comprises a sealing adaptor 246 mounted on an end of the drug container facing an outer side of the plunger (fig. 5B), the sealing adaptor comprising a sealing plug inserted inside an end of the barrel portion (fig. 5B; page 4, para. 0054), the sealing plug comprising an orifice 246a configured for pluggable sealing connection to a gas channel connector (distal portion of 256 received in channel 246a) of the pneumatic flow system (fig. 5b; page 4, para. 0054). Regarding claim 2, Mojarrad discloses that the gas channel connector comprises a tubular end portion pluggably inserted in the orifice of the sealing plug (fig. 5b). Regarding claim 3, Mojarrad discloses that the sealing plug comprises an inner radial sealing ring comprising a portion extending axially from an end wall of the sealing plug, said orifice for sealing connection to the gas channel connector being formed within the inner radial sealing ring (see fig. 5B annotated below). PNG media_image1.png 547 813 media_image1.png Greyscale Regarding claim 4, Mojarrad discloses that the plunger comprises a back end forming a cavity (fig. 6), said axial extension of the inner radial sealing ring being positioned at least partially in the cavity in an initial position prior to drug delivery (fig. 6: portion 248 forming part of the axial extension is at least partially received in the cavity). Regarding claim 5, Mojarrad discloses that the sealing plug comprises an outer radial sealing ring 246b comprising a portion extending axially from an end wall of the sealing plug, the outer radial sealing ring sealingly engaging an inner surface of the barrel portion of the drug container (fig. 5B; page 4, para. 0054). Regarding claim 6, Mojarrad discloses that the sealing adaptor comprises a cap inserted over an end of the barrel portion (see fig. 7 annotated below), the cap comprising an end wall engaging a back end of the sealing plug and one or more locking members engaging a housing component of the delivery unit in which the drug container is received (see fig. 7 annotated below). PNG media_image2.png 866 1162 media_image2.png Greyscale Regarding claim 7, The drug delivery device according to claim 6, wherein the housing component of the delivery unit is a container casing within which the drug container is inserted in the delivery unit, the locking member of the sealing adaptor cap engaging the complementary locking member on the container casing. Regarding claim 10, Mojarrad discloses that the pneumatic flow system comprises a channel housing 250 component within which a gas channel 256 is formed extending between the gas channel connector and the outlet of the pump engine (fig. 5B). Regarding claim 11, Mojarrad discloses that the gas channel housing component is formed as a separated part assembled in the drive unit to the pump engine (fig. 5B shows all separate assembled components). Regarding claim 13, Mojarrad discloses that the drug container is a drug cartridge 242’ and comprises a septum 214’ at one end (fig. 7). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mojarrad in view of Wyssman (US 5,741,275). Claim 8 calls for the one or more locking members on the cap comprises one or more elastic latches having a locking shoulder engaging a complementary locking shoulder on the outside of the container casing. Mojarrad shows locking members as discussed above with regard to claim 6, but fails to disclose that they are elastic. Wyssman teaches a cap 1159 having elastic latches with a locking shoulder for engaging a complementary locking shoulder on the outside of the container casing to provide a secure connection that is easy to assembly (col. 6, lines 55-61; fig. 12a). it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the cap of Mojarrad to include one or more elastic latches as taught by Wyssman to allow for easy connection of the cap to the device and provide secure connection thereto. Allowable Subject Matter Claims 9, 12, 14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: the subject matter of the listed claims could not be found in combination with the features of the invention, substantially as claimed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA A BOUCHELLE whose telephone number is (571)272-2125. The examiner can normally be reached Mon-Fri 8:00-5:00 CST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bhisma Mehta can be reached at 571-272-3383. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LAURA A. BOUCHELLE Primary Examiner Art Unit 3783 /LAURA A BOUCHELLE/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Sep 07, 2023
Application Filed
Feb 05, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594377
SYSTEMS AND METHODS FOR DELIVERING MICRODOSES OF MEDICATION
2y 5m to grant Granted Apr 07, 2026
Patent 12589205
WET INJECTION DETECTION AND PREVENTION SYSTEM AND METHOD
2y 5m to grant Granted Mar 31, 2026
Patent 12589025
INTRAOCULAR DEVICES, SYSTEMS, AND METHODS
2y 5m to grant Granted Mar 31, 2026
Patent 12589026
MICRO DOSING DEVICE AND METHOD OF ASSEMBLY OF THE MICRO DOSING DEVICE
2y 5m to grant Granted Mar 31, 2026
Patent 12589221
MECHANICALLY-DECOUPLED ACTUATION FOR ROBOTIC CATHETER SYSTEM
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
90%
With Interview (+10.3%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 1188 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month